/NBTX
NBTX Stock - Nanobiotix S.A.
Healthcare|BiotechnologyNASDAQ
$21.38+6.53%
+$1.31 (+6.53%) • Jan 13
83
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.81
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).93
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+21.6%upside
Target: $26.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NBTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$21.17 – $21.59
TARGET (TP)$26.00
STOP LOSS$19.67
RISK/REWARD1:2.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.47
52W High$30.35
52W Low$2.85
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $-11,609,000 | $36.21M | $4.78M | $2.65M | $50,000 |
| Gross Profit | $-11,609,000 | $36.21M | $3.79M | $2.65M | $50,000 |
| Gross Margin | 100.0% | 100.0% | 79.4% | 100.0% | 100.0% |
| Operating Income | $-68,392,000 | $-26,779,000 | $-46,702,000 | $-52,579,000 | $-36,428,000 |
| Net Income | $-68,132,000 | $-39,700,000 | $-57,043,000 | $-47,004,000 | $-33,623,000 |
| Net Margin | 586.9% | -109.6% | -1194.4% | -1775.7% | -67246.0% |
| EPS | $-1.44 | $-1.08 | $-1.64 | $-1.35 | $-1.38 |
Company Overview
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NBTXBeat Rate
67%
Last 9 quarters
Avg Surprise
+2.4%
EPS vs Estimate
Beats / Misses
6/3
Last 12 quarters
Latest EPS
$-0.13
Q3 2025
EPS Surprise History
Q1 22
+48.6%
$-0.54vs$-1.05
Q4 22
No data
Q1 23
No data
Q4 23
-47.6%
$-0.87vs$-0.59
Q2 24
+60.4%
$-0.33vs$-0.83
Q4 24
+2.5%
$-0.50vs$-0.51
Q2 25
-63.5%
$-1.01vs$-0.62
Q3 25
+45.9%
$-0.13vs$-0.25
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 19, 2026 | — | — | — | — |
Q3 2025 | Sep 30, 2025 | $-0.25 | $-0.13 | +45.9% | ✓ BEAT |
Q2 2025 | Apr 2, 2025 | $-0.62 | $-1.01 | -63.5% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.51 | $-0.50 | +2.5% | ✓ BEAT |
Q2 2024 | Apr 24, 2024 | $-0.83 | $-0.33 | +60.4% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.59 | $-0.87 | -47.6% | ✗ MISS |
Q1 2023 | Mar 28, 2023 | — | $-0.95 | — | — |
Q4 2022 | Nov 9, 2022 | — | $-0.79 | — | — |
Q1 2022 | Mar 30, 2022 | $-1.05 | $-0.54 | +48.6% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-0.60 | $-1.04 | -73.8% | ✗ MISS |
Q2 2021 | May 5, 2021 | $-1.01 | $-0.57 | +43.1% | ✓ BEAT |
Q4 2020 | Oct 23, 2020 | $-1.09 | $-1.02 | +5.9% | ✓ BEAT |
Q2 2020 | Apr 30, 2020 | — | $-1.37 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-1.30 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-1.08 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.75 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.86 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.87 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.79 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.76 | — | — |
Latest News
Loading news...
Frequently Asked Questions about NBTX
What is NBTX's current stock price?
Nanobiotix S.A. (NBTX) is currently trading at $21.38 per share. The stock has moved +6.53% today.
What is the analyst price target for NBTX?
The average analyst price target for NBTX is $26.00, based on 1 analyst.
What sector is Nanobiotix S.A. in?
Nanobiotix S.A. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NBTX's market cap?
Nanobiotix S.A. has a market capitalization of $1.01 billion, making it a small-cap company.
Does NBTX pay dividends?
No, Nanobiotix S.A. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABUS
Arbutus Biopharma Corporation
$4.74
Mkt Cap: $0.9B
EYPT
EyePoint Pharmaceuticals, Inc.
$15.93
Mkt Cap: $1.3B
GHRS
GH Research PLC
$15.84
Mkt Cap: $1.0B
KURA
Kura Oncology, Inc.
$9.21
Mkt Cap: $0.8B
LENZ
LENZ Therapeutics, Inc.
$16.60
Mkt Cap: $0.5B
PROK
ProKidney Corp.
$2.29
Mkt Cap: $0.3B
RZLT
Rezolute, Inc.
$2.48
Mkt Cap: $0.2B
SPRY
ARS Pharmaceuticals, Inc.
$11.31
Mkt Cap: $1.1B
SVRA
Savara Inc.
$5.92
Mkt Cap: $1.2B
TYRA
Tyra Biosciences, Inc.
$28.81
Mkt Cap: $1.5B
Explore stocks similar to NBTX for comparison